Prognostic and predictive factors in high-grade gliomas. Experience at our institution

被引:0
|
作者
Alonso, Diana [1 ]
Matallanas, Manuel [1 ]
Riveros-Perez, Alba [2 ]
Perez-Payo, Maripaz [1 ]
Blanco, Sonia [1 ]
机构
[1] HUCA, Serv Oncol Radioterap, Oviedo, Spain
[2] Hosp Univ Doctor Negrin, Serv Oncol Radioterap, Las Palmas Gran Canaria, Las Palmas, Spain
来源
NEUROCIRUGIA | 2017年 / 28卷 / 06期
关键词
Glioma; Glioblastoma; Astrocytoma; GLIOBLASTOMA; MGMT; CLASSIFICATION; TEMOZOLOMIDE; METHYLATION; TUMORS;
D O I
10.1016/j.neucie.2017.07.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objectiue: To describe and analyse predictive and prognostic factors of overall survival (OS) in high-grade gliomas at our institution. Material and method: All patients diagnosed with grade in (GIII) or grade iv (GIV) gliomas (excluding oligodendrogliomas, oligoastrocytomas or infratentorial gliomas) were prospectively included from November 2010 to August 2014. All were treated with surgery followed by adjuvant radiochemotherapy. The Kaplan-Meier method was used for the statistical analysis, considering a P value <.05 to be significant. Results: 89 patients were studied (18 GIII and 71 GIV). The average age was 60 years and 55% were men. The mean Karnofsky score was 80%. The most common location was the frontal lobe (38%). A total of 65% were partial resections. Complete chemotherapy was administered to 74% and complete RT to 83% of patients. Mean OS was 26.8 8.3 months for GIII and 12.5 1 month for GIV. 72 had died by the end of this study. A total of 40% of patients had MGMT methylation, 7% IDH1 mutation and 47% EGFR amplification. Statistically significant variables for OS were: GIII (P=.020), age <70 years (P=.040), <65 years (P=.013) and <60 years (P=.003), Kamofsky >70% (P=.029), complete radiotherapy (P=.000), complete resection (P=.001), MGMT methylation (P=.042), IDH1 mutation (P=.007) and EGFR non-amplification (P=.034). Additionally, GIII and GN subgroups were independently analysed. In GIII, the only significant biomarker for OS was IDH1 mutation, while in GN, MGMT methylation (P=.023) was significant. Age >70 years old was a significant factor in the GIII-subgroup (P=.040) but not for GIV (P=.166). Conclusions: Data are in line with previous studies, with the exception of age, which does not appear to be significant in GIV. 2017 Sociedad Espanola de Neurocirugia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 50 条
  • [21] Feasibility of lymphocyte harvesting and reinfusion in patients with newly diagnosed high-grade gliomas.
    Campian, Jian Li
    Ye, Xiaobu
    Gladstone, Douglas Edward
    Ambady, Prakash
    Borrello, Ivan
    Golightly, Marc
    Karen, Karen E. King
    King, E.
    Holdhoff, Matthias
    Karp, Judith E.
    Grossman, Stuart A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Factors influencing survival in high-grade gliomas
    Buckner, JC
    SEMINARS IN ONCOLOGY, 2003, 30 (06) : 10 - 14
  • [23] Simultaneous Integrated Boost Technique for Pediatric High-Grade Gliomas: A Single-Institution Experience
    Matsui, J. K.
    Johnson, J. M.
    Paulino, A. C.
    McAleer, M. F.
    Grosshans, D. R.
    Ghia, A. J.
    Li, J.
    Zaky, W.
    Chintagumpala, M.
    McGovern, S. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E482 - E483
  • [24] Synergistic effect of reirradiation and PD-1 inhibitors in recurrent high-grade gliomas.
    Iwamoto, Fabio Massaiti
    Donovan, Laura
    Schaff, Lauren R.
    Wang, Tony J. C.
    Lassman, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [25] High-Grade Gliomas
    Brett J. Theeler
    Morris D. Groves
    Current Treatment Options in Neurology, 2011, 13 : 386 - 399
  • [26] Prognostic Factors in Elderly Patients with High-grade Gliomas: A Retrospective Analysis of 24 Cases
    Gupta, Meenu
    Bansal, Saurabh
    Pruthi, Deep Shankar
    Saini, Manju
    Shirazi, Nadia
    Ahmad, Mushtaq
    JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2018, 9 (03) : 312 - 316
  • [27] Prognostic factors in High-Grade Localized Osteosarcoma of the Extremities: The Tunisian Experience
    Letaief, Feryel
    Khrouf, Salim
    Yahiaoui, Yosra
    Hamdi, Adel
    Gabsi, Azza
    Ayadi, Mouna
    Mezlini, Amel
    JOURNAL OF ORTHOPAEDIC SURGERY, 2020, 28 (03)
  • [28] High-Grade Gliomas
    Theeler, Brett J.
    Groves, Morris D.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2011, 13 (04) : 386 - 399
  • [29] High-grade gliomas
    Haase, Jens
    SURGICAL NEUROLOGY, 2008, 70 (06): : 598 - 598
  • [30] CHEMOTHERAPY FOR PEDIATRIC HIGH-GRADE GLIOMAS: THE FLORENTINE EXPERIENCE
    Lucchesi, Maurizio
    Guidi, Milena
    Fonte, Carla
    Farina, Silvia
    Favre, Claudio
    Genitori, Lorenzo
    Sardi, Iacopo
    NEURO-ONCOLOGY, 2016, 18 : 54 - 54